Biomarkers in nephrology: Core curriculum 2013

American Journal of Kidney Diseases

Volumn 62, Issue 1, 2013, Pages 165-178

  McMahon, Gearoid M ^a   Waikar, Sushrut S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CREATININE; CYSTATIN C; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OSTEOPONTIN;

ACUTE KIDNEY FAILURE; ALBUMINURIA; ARTICLE; CHRONIC KIDNEY DISEASE; GLOMERULONEPHRITIS; GLOMERULOPATHY; KIDNEY FUNCTION; NEPHROLOGY; NEPHRON; NEPHROTOXICITY; PLASMA; SCORING SYSTEM; SERUM; URINE SEDIMENT;

ANIMALS; BIOLOGICAL MARKERS; CREATININE; CURRICULUM; CYSTATIN C; HUMANS; KIDNEY DISEASES; NEPHROLOGY;

EID: 84879412067     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2012.12.022     Document Type: Article

References (81)

1. Carrie BJ, Golbetz HV, Michaels AS, Myers BD. Creatinine: an inadequate filtration marker in glomerular diseases. Am J Med. 1980;69(2):177-182.
2. Hankins DA, Babb AL, Uvelli DA, Scribner BH. Creatinine degradation I: the kinetics of creatinine removal in patients with chronic kidney disease. Int J Artif Organs. 1981;4(1):35-39.
3. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem. 1992;38(10):1933-1953.
4. Rehberg PB. Studies on kidney function: the rate of filtration and reabsorption in the human kidney. Biochem J. 1926;20(3): 447-460.
5. Briguori C, Visconti G, Rivera NV, et al. Cystatin C and contrast-induced acute kidney injury. Circulation. 2010; 121(19):2117-2122.
6. Demirtas S, Akan O, Can M, Elmali E, Akan H. Cystatin C can be affected by nonrenal factors: a preliminary study on leukemia. Clin Biochem. 2006;39(2):115-118.
7. Edelstein CL. Biomarkers in Kidney Disease. 1st ed. Amsterdam, the Netherlands: Academic Press/Elsevier; 2011.
8. Grubb A. Diagnostic value of analysis of cystatin C and protein HC in biological fluids. Clin Nephrol. 1992;38(suppl 1):S20-S27.
9. Herget-Rosenthal S, Marggraf G, Husing J, et al. Early detection of acute renal failure by serum cystatin C. Kidney Int. 2004;66(3):1115-1122.
10. Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20-29.
11. Manzano-Fernandez S, Januzzi JL Jr, Boronat-Garcia M, et al. Beta-trace protein and cystatin C as predictors of longterm outcomes in patients with acute heart failure. J Am Coll Cardiol. 2011;57(7):849-858.
12. Nejat M, Hill JV, Pickering JW, Edelstein CL, Devarajan P, Endre ZH. Albuminuria increases cystatin C excretion: implications for urinary biomarkers. Nephrol Dial Transplant. 2011;27 Suppl 3:iii96-103.
13. Nejat M, Pickering JW, Walker RJ, Endre ZH. Rapid detection of acute kidney injury by plasma cystatin C in the intensive care unit. Nephrol Dial Transplant. 2010;25(10): 3283-3289.
14. Priem F, Althaus H, Jung K, Sinha P. Beta-trace protein is not better than cystatin C as an indicator of reduced glomerular filtration rate. Clin Chem. 2001;47(12):2181.
15. Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352(20):2049-2060.
16. Spahillari A, Parikh CR, Sint K, et al. Serum cystatin Cversus creatinine-based definitions of acute kidney injury following cardiac surgery: a prospective cohort study. Am J Kidney Dis. 2012;60(6):922-929.
17. Fogazzi GB, Ponticelli C, Ritz E. The Urine Sediment: An Integrated View, 3rd edition. Milan, Italy: Elsevier Srl; 2010.
18. Hall IE, Coca SG, Perazella MA, et al. Risk of poor outcomes with novel and traditional biomarkers at clinical AKI diagnosis. Clin J Am Soc Nephrol. 2011;6(12):2740-2749.
19. Perazella MA, Coca SG. Traditional urinary biomarkers in the assessment of hospital-acquired AKI. Clin J Am Soc Nephrol. 2011;7(1):167-174.
20. Perazella MA, Coca SG, Hall IE, Iyanam U, Koraishy M, Parikh CR. Urine microscopy is associated with severity and worsening of acute kidney injury in hospitalized patients. Clin J Am Soc Nephrol. 2010;5(3):402-408.
21. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073-2081.
22. Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011; 80(1):17-28.
23. Dieterle F, Sistare F, Goodsaid F, et al. Renal biomarker qualification submission: a dialog between the FDA-EMEA and predictive safety testing consortium. Nat Biotechnol. 2010;28(5):455-462.
24. Edelstein CL. Biomarkers in Kidney Disease. 1st ed. Amsterdam, the Netherlands: Academic Press/Elsevier; 2011.
25. Endre ZH, Pickering JW, Walker RJ. Clearance and beyond: the complementary roles of GFR measurement and injury biomarkers in acute kidney injury (AKI). Am J Physiol Renal Physiol. 2011;301(4):F697-F707.
26. Haase M, Devarajan P, Haase-Fielitz A, et al. The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. J Am Coll Cardiol. 2011;57(17):1752-1761.
27. Nejat M, Pickering JW, Devarajan P, et al. Some biomarkers of acute kidney injury are increased in pre-renal acute injury. Kidney Int. 2012;81(12):1254-1262.
28. Ozer JS, Dieterle F, Troth S, et al. A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nat Biotechnol. 2010;28(5):486-494.
29. Waikar SS, Betensky RA, Emerson SC, Bonventre JV. Imperfect gold standards for kidney injury biomarker evaluation. J Am Soc Nephrol. 2012;23(1):13-21.
30. Edelstein CL. Biomarkers in Kidney Disease. 1st ed. Amsterdam, the Netherlands: Academic Press/Elsevier; 2011.
31. Hewitt SM, Dear J, Star RA. Discovery of protein biomarkers for renal diseases. J Am Soc Nephrol. 2004;15(7):1677-1689.
32. Wu J, Chen YD, GuW. Urinary proteomics as a novel tool for biomarker discovery in kidney diseases. J Zhejiang Univ Sci B. 2010;11(4):227-237.
33. Conti M, Moutereau S, Esmilaire L, et al. Should kidney tubular markers be adjusted for urine creatinine? The example of urinary cystatin C. Clin Chem Lab Med. 2009;47(12):1553-1556.
34. Jantos-Siwy J, Schiffer E, Brand K, et al. Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. J Proteome Res. 2009;8(1):268-281.
35. Ralib AM, Pickering JW, Shaw GM, et al. Test characteristics of urinary biomarkers depend on quantitation method in acute kidney injury. J Am Soc Nephrol. 2012;23(2):322-333.
36. Waikar SS, Sabbisetti VS, Bonventre JV. Normalization of urinary biomarkers to creatinine during changes in glomerular filtration rate. Kidney Int. 2010;78(5):486-494.
37. Amin AP, Salisbury AC, McCullough PA, et al. Trends in the incidence of acute kidney injury in patients hospitalized with acute myocardial infarction. Arch Intern Med. 2012;172(3): 246-253.
38. Bagshaw SM, Langenberg C, Haase M, Wan L, May CN, Bellomo R. Urinary biomarkers in septic acute kidney injury. Intensive Care Med. 2007;33(7):1285-1296.
39. Bellomo R, Kellum JA, Ronco C. Acute kidney injury. Lancet. 2012;380(9843):756-766.
40. Bonventre JV. Kidney injury molecule-1 (KIM-1): a urinary biomarker and much more. Nephrol Dial Transplant. 2009; 24(11):3265-3268.
41. Edelstein CL. Biomarkers in Kidney Disease. 1st ed. Amsterdam, the Netherlands: Academic Press/Elsevier; 2011.
42. Koyner JL, Garg AX, Coca SG, et al. Biomarkers predict progression of acute kidney injury after cardiac surgery. J Am Soc Nephrol. 2012;23(5):905-914.
43. Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase- Fielitz A; NGAL Meta-analysis Investigator Group. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 2009;54(6):1012-1024.
44. Haase M, Bellomo R, Story D, Davenport P, Haase-Fielitz A. Urinary interleukin-18 does not predict acute kidney injury after adult cardiac surgery: a prospective observational cohort study. Crit Care. 2008;12(4):R96.
45. Haase M, Devarajan P, Haase-Fielitz A, et al. The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. J Am Coll Cardiol. 2011;57(17):1752-1761.
46. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. 2002;62(1): 237-244.
47. Liangos O, Perianayagam MC, Vaidya VS, et al. Urinary N-acetyl-beta-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol. 2007;18(3):904-912.
48. Lisowska-Myjak B. Serum and urinary biomarkers of acute kidney injury. Blood Purif. 2010;9(4):357-365.
49. Mishra J, Ma Q, Prada A, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol. 2003; 14(10):2534-2543.
50. Parikh CR, Coca SG, Thiessen-Philbrook H, et al. Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery. J Am Soc Nephrol. 2011; 22(9):1748-1757.
51. Parikh CR, Jani A, Melnikov VY, Faubel S, Edelstein CL. Urinary interleukin-18 is a marker of human acute tubular necrosis. Am J Kidney Dis. 2004;43(3):405-414.
52. Parikh CR, Mishra J, Thiessen-Philbrook H, et al. Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. Kidney Int. 2006;70(1):199-203.
53. Urbschat A, Obermuller N, Haferkamp A. Biomarkers of kidney injury. Biomarkers. 2011;16(suppl 1):S22-S30.
54. Waikar SS, Betensky RA, Bonventre JV. Creatinine as the gold standard for kidney injury biomarker studies? Nephrol Dial Transplant. 2009;24(11):3263- 3265.
55. Waring WS, Moonie A. Earlier recognition of nephrotoxicity using novel biomarkers of acute kidney injury. Clin Toxicol (Phila). 2011;49(8):720-728.
56. Yu Y, Jin H, Holder D, et al. Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury. Nat Biotechnol. 2010;28(5):470-477.
57. Bolignano D, Lacquaniti A, Coppolino G, et al. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(2):337-344.
58. Fassett RG, Venuthurupalli SK, Gobe GC, Coombes JS, Cooper MA, Hoy WE. Biomarkers in chronic kidney disease: a review. Kidney Int. 2011;80(8):806-821.
59. Kamijo-Ikemori A, Sugaya T, Yasuda T, et al. Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients. Diabetes Care. 2011;34(3):691-696.
60. Lu TM, Chung MY, Lin CC, Hsu CP, Lin SJ. Asymmetric dimethylarginine and clinical outcomes in chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(7):1566-1572.
61. Manzano-Fernandez S, Januzzi JL, Boronat-Garcia M, et al. Impact of kidney dysfunction on plasma and urinary Nterminal pro-B-type natriuretic peptide in patients with acute heart failure. Congest Heart Fail. 2010;16(5):214-220.
62. Priem F, Althaus H, Jung K, Sinha P. Beta-trace protein is not better than cystatin C as an indicator of reduced glomerular filtration rate. Clin Chem. 2001;47(12):2181.
63. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol. 2005;16(8):2449-2455.
64. Spanaus KS, Kollerits B, Ritz E, et al. Serum creatinine, cystatin C, and beta-trace protein in diagnostic staging and predicting progression of primary nondiabetic chronic kidney disease. Clin Chem. 2010;56(5):740-749.
65. Waanders F, Vaidya VS, van Goor H, et al. Effect of renin-angiotensin- aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial. Am J Kidney Dis. 2009;53(1):16-25.
66. Ali BH, Al-Salam S, Al-Husseini I, Nemmar A. Comparative protective effect of N-acetyl cysteine and tetramethylpyrazine in rats with gentamicin nephrotoxicity. J Appl Toxicol. 2009;29(4):302-307.
67. Hoffmann D, Fuchs TC, Henzler T, et al. Evaluation of a urinary kidney biomarker panel in rat models of acute and subchronic nephrotoxicity. Toxicology. 2010;277(1-3):49-58.
68. Waring WS, Moonie A. Earlier recognition of nephrotoxicity using novel biomarkers of acute kidney injury. Clin Toxicol (Phila). 2011;49(8):720-728.
69. Zhou Y, Vaidya VS, Brown RP, et al. Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromium. Toxicol Sci. 2008;101(1):159-170.
70. Avihingsanon Y, Phumesin P, Benjachat T, et al. Measurement of urinary chemokine and growth factor messenger RNAs: a noninvasive monitoring in lupus nephritis. Kidney Int. 2006;69(4):747-753.
71. Bazzi C, Rizza V, Raimondi S, Casellato D, Napodano P, DAmico G. In crescentic IgA nephropathy, fractional excretion of IgG in combination with nephron loss is the best predictor of progression and responsiveness to immunosuppression. Clin J Am Soc Nephrol. 2009;4(5):929-935.
72. Brunner HI, Bennett MR, Mina R, et al. Non-invasive renal protein biomarkers are associated with histological features of lupus nephritis. Arthritis Rheum. 2012;64(8):2687-2697.
73. Haubitz M, Good DM, Woywodt A, et al. Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-neutrophil cytoplasmic antibody-associated vasculitis. Mol Cell Proteomics. 2009;8(10):2296-2307.
74. Herrmann SM, Sethi S, Fervenza FC. Membranous nephropathy: the start of a paradigm shift. Curr Opin Nephrol Hypertens. 2012;21(2):203-210.
75. Pitashny M, Schwartz N, Qing X, et al. Urinary lipocalin-2 is associated with renal disease activity in human lupus nephritis. Arthritis Rheum. 2007;56(6):1894-1903.
76. Romick-Rosendale LE, Brunner HI, Bennett MR, et al. Identification of urinary metabolites that distinguish membranous lupus nephritis from proliferative lupus nephritis and focal segmental glomerulosclerosis. Arthritis Res Ther. 2011; 13(6):R199.
77. Rubinstein T, Pitashny M, Levine B, et al. Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. Rheumatology (Oxford). 2010;49(5):960-971.
78. Stangou M, Alexopoulos E, Papagianni A, et al. Urinary levels of epidermal growth factor, interleukin-6 and monocyte chemoattractant protein-1 may act as predictor markers of renal function outcome in immunoglobulinAnephropathy. Nephrology (Carlton). 2009;4(6):613-620.
79. Wei C, El Hindi S, Li J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med. 2011;17(8):952-960.
80. Zhang X, Nagaraja HN, Nadasdy T, et al. A composite urine biomarker reflects interstitial inflammation in lupus nephritis biopsies. Kidney Int. 2012;81(4):401-406
81. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89-95. Diseases Diseases Diseases